These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29729048)

  • 1. Regional variations in definitions and rates of hypoglycaemia: findings from the global HAT observational study of 27 585 people with Type 1 and insulin-treated Type 2 diabetes mellitus.
    Khunti K; Cigrovski Berković M; Ludvik B; Moberg E; Barner Lekdorf J; Gydesen H; Pedersen-Bjergaard U
    Diabet Med; 2018 May; 35(9):1232-41. PubMed ID: 29729048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study.
    Khunti K; Alsifri S; Aronson R; Cigrovski Berković M; Enters-Weijnen C; Forsén T; Galstyan G; Geelhoed-Duijvestijn P; Goldfracht M; Gydesen H; Kapur R; Lalic N; Ludvik B; Moberg E; Pedersen-Bjergaard U; Ramachandran A;
    Diabetes Obes Metab; 2016 Sep; 18(9):907-15. PubMed ID: 27161418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Self-reported Hypoglycaemic Events in 2 430 Patients with Insulin-treated Diabetes in the German Sub-population of the HAT Study.
    Kern W; Holstein A; Moenninghoff C; Kienhöfer J; Riedl M; Kulzer B
    Exp Clin Endocrinol Diabetes; 2017 Oct; 125(9):592-597. PubMed ID: 28750429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes.
    Khunti K; Alsifri S; Aronson R; Cigrovski Berković M; Enters-Weijnen C; Forsén T; Galstyan G; Geelhoed-Duijvestijn P; Goldfracht M; Gydesen H; Kapur R; Lalic N; Ludvik B; Moberg E; Pedersen-Bjergaard U; Ramachandran A;
    Diabetes Res Clin Pract; 2017 Aug; 130():121-129. PubMed ID: 28602812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct and indirect health economic impact of hypoglycaemia in a global population of patients with insulin-treated diabetes.
    Aronson R; Galstyan G; Goldfracht M; Al Sifri S; Elliott L; Khunti K
    Diabetes Res Clin Pract; 2018 Apr; 138():35-43. PubMed ID: 29355651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real-world studies.
    Pedersen-Bjergaard U; Alsifri S; Aronson R; Berković MC; Galstyan G; Gydesen H; Lekdorf JB; Ludvik B; Moberg E; Ramachandran A; Khunti K
    Diabetes Obes Metab; 2019 Apr; 21(4):844-853. PubMed ID: 30456887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoglycaemia among Insulin-Treated Patients with Diabetes: Southeast Asia Cohort of IO HAT Study.
    Pathan F; Goh SY; Rudijanto A; Gadekar A; Jain A; Nicodemus N
    J ASEAN Fed Endocr Soc; 2018; 33(1):28-36. PubMed ID: 33442108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-reported non-severe hypoglycaemic events in Europe.
    Östenson CG; Geelhoed-Duijvestijn P; Lahtela J; Weitgasser R; Markert Jensen M; Pedersen-Bjergaard U
    Diabet Med; 2014 Jan; 31(1):92-101. PubMed ID: 23796113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia.
    Swinnen SG; Mullins P; Miller M; Hoekstra JB; Holleman F
    Diabetologia; 2009 Jan; 52(1):38-41. PubMed ID: 18806996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global burden of hypoglycaemia-related mortality in 109 countries, from 2000 to 2014: an analysis of death certificates.
    Zaccardi F; Dhalwani NN; Webb DR; Davies MJ; Khunti K
    Diabetologia; 2018 Jul; 61(7):1592-1602. PubMed ID: 29717336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia.
    Heller S; Mathieu C; Kapur R; Wolden ML; Zinman B
    Diabet Med; 2016 Apr; 33(4):478-87. PubMed ID: 26484727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
    Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
    Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous glucose monitoring versus blood glucose monitoring for risk of severe hypoglycaemia and diabetic ketoacidosis in children, adolescents, and young adults with type 1 diabetes: a population-based study.
    Karges B; Tittel SR; Bey A; Freiberg C; Klinkert C; Kordonouri O; Thiele-Schmitz S; Schröder C; Steigleder-Schweiger C; Holl RW
    Lancet Diabetes Endocrinol; 2023 May; 11(5):314-323. PubMed ID: 37004710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biphasic insulin aspart 30 in insulin-naive people with type 2 diabetes in non-western nations: results from a regional comparative multinational observational study (A(1)chieve).
    Shah S; Yang W; Hasan MI; Malek R; Molskov Bech O; Home P
    Diabetes Technol Ther; 2013 Nov; 15(11):954-63. PubMed ID: 24053450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
    Philis-Tsimikas A; Klonoff DC; Khunti K; Bajaj HS; Leiter LA; Hansen MV; Troelsen LN; Ladelund S; Heller S; Pieber TR;
    Diabetologia; 2020 Apr; 63(4):698-710. PubMed ID: 31984443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non-interventional study (EU-TREAT).
    Knudsen ST; Lapolla A; Schultes B; Tentolouris N; Catarig AM; Wolden ML; Siegmund T
    Diabet Med; 2019 Jul; 36(7):868-877. PubMed ID: 31001865
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.